Expedited Access to Biosimilars Act

# Expedited Access to Biosimilars Act Summary **What the Bill Does** This bill would speed up the approval process for biosimilars—drugs that are highly similar to existing biologic medications already approved by the FDA. Biosimilars are typically less expensive alternatives to brand-name biologic drugs. The bill aims to reduce the time and regulatory barriers needed for these cheaper medications to reach the market and become available to patients. **Who It Affects** The bill would primarily affect patients who use biologic medications (drugs made from living cells), insurance companies that pay for prescriptions, pharmaceutical manufacturers developing biosimilars, and brand-name drug manufacturers.

Patients could potentially benefit from lower-cost treatment options, while the healthcare system overall might see reduced medication costs. **Key Provisions & Current Status** While specific details aren't provided in the summary, expedited biosimilar bills typically include measures like streamlined FDA review timelines and reduced data requirements for approval. The bill is currently in committee, meaning it has been introduced in the Senate but has not yet advanced to a full vote. It requires further discussion and approval by committee members before it could move forward for consideration by the full Senate.